Therapeutic uses of anti-interleukin-6 receptor antibody

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

(2014) Manabu Araki et al.   Modern Rheumatology

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study

(2014) M. Araki et al.   NEUROLOGY

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy

(2014) Toshio Tanaka et al.   SEMINARS IN IMMUNOLOGY

The Biology and Medical Implications of Interleukin-6

(2014) T. Tanaka et al.   Cancer Immunology Research

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression

(2013) Naoshi Nishina et al.   CLINICAL RHEUMATOLOGY

The roles of aryl hydrocarbon receptor in immune responses

(2013) Nam Trung Nguyen et al.   INTERNATIONAL IMMUNOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo

(2013) Kazuya Masuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

(2013) Soken-Nakazawa J Song et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy

(2013) Ilya Ayzenberg et al.   JAMA Neurology

Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis

(2013) A. Thiolat et al.   Arthritis & Rheumatology

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

(2012) Maxime Samson et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients

(2012) B. Pesce et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The origins, function, and regulation of T follicular helper cells

(2012) Cindy S. Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Targeting of the Interleukin-6 Receptor

(2011) Toshio Tanaka et al.   Annual Review of Pharmacology and Toxicology

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR–IL-1R by controlling degradation of regnase-1

(2011) Hidenori Iwasaki et al.   NATURE IMMUNOLOGY

Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis

(2011) T. Nakahama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

(2011) Norio Chihara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-6: Regulator of Treg/Th17 balance

(2010) Akihiro Kimura et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

(2010) N. T. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses

(2009) Akihiro Kimura et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay

(2009) Kazufumi Matsushita et al.   NATURE

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET

The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins

(2008) Marc Veldhoen et al.   NATURE

Post-transcriptional control of cytokine production

(2008) Paul Anderson   NATURE IMMUNOLOGY